Fighting leukemia with “duel”-targeted therapy

Article Tools

• Email

  Thank you for your interest in spreading the word about Science Translational Medicine.

  NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

  Your Email

  Your Name

  Send To

  Enter multiple addresses on separate lines or separate them with commas.

  You are going to email the following Fighting leukemia with “duel”-targeted therapy

  Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

  Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

  Your Personal Message

  Send Message
• Save to my folders

  User Name

  Password

  Remember my user name & password.

  Submit
• Alerts

  Please log in to add an alert for this article.

  Username Enter your Sciencemag.org username.

  Password Enter the password that accompanies your username.

  Log in
• Citation tools

  Fighting leukemia with “duel”-targeted therapy

  By Tríona Ní Chonghaile

  Science Translational Medicine04 Apr 2018

  Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.

  Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
• Share

  Fighting leukemia with “duel”-targeted therapy

  By Tríona Ní Chonghaile

  Science Translational Medicine04 Apr 2018

  Combining BCL-2 inhibitor venetoclax with monoclonal CD20 antibody rituximab greatly enhances progression-free survival compared with bendamustine-rituximab in a phase 3 trial of relapsed or refractory chronic lymphocytic leukemia patients.

  Share This Article: Copy